The American Society of Pediatric Hematology/Oncology workforce assessment: Part 2—Implications for fellowship training

Leavey, Patrick J.; Hilden, Joanne M.; Matthews, Dana C.; Dandoy, Christopher E.; Badawy, Sherif M.; Shah, Mona D.; Wayne, Alan S.; Hord, Jeff D.

doi:10.1002/pbc.26765

Cited by 14 publications

(27 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The pathophysiology of ABC seems to be similar to this [29,36]. Denosumab, which effectively blocks interaction between RANKL and RANK has been approved for the treatment of osteoporosis, metastatic bone disease, multiple myeloma and GCT [19,37]. The use of denosumab as an adjuvant treatment in patients with GCT has shown a high rate of recalcification [38].…”

Section: Discussionmentioning

confidence: 96%

See 1 more Smart Citation

Aneurysmal bone cyst: results of an off label treatment with Denosumab

Dürr¹,

Grahneis²,

Baur‐Melnyk

et al. 2019

BMC Musculoskelet Disord

View full text Add to dashboard Cite

Background: The treatment of aneurysmal bone cysts (ABCs) has evolved and less invasive methods have been tried. Denosumab is a monoclonal antibody which inhibits osteoclasts. It has been shown to be effective in giant cell tumour of bone (GCT) of bone and hence promises some effect also in ABC. We report on 6 patients treated with Denosumab and compare our results to the cases already published. Methods: Data of 6 patients with ABCs and patients whose treatment included Denosumab were retrospectively analyzed. Denosumab was used at a dose of 120 mg on days 1, 8, 15 and 29, and every 4 weeks thereafter. In some of these patients the dose was reduced at the end of the treatment. Clinical and radiological responses were evaluated. Results: In 4 female and 2 male patients with a mean age of 17 years (range: 6-30 years) the lesions were located in the sacrum (2), in distal radius, distal femur, talus and pelvis. One of the sacral lesions healed after 12 months and has stayed stable for 3 years since. The second patient received 2 years of therapy with recalcification, but recurred 1 year later and is under renewed therapy. The pelvic lesion improved but recurred. This patient has a 13-years history of intermittent therapy including surgery, two pregnancies and remains in a stable situation. The lesion of the talus did not improve with Denosumab after surgery and was complicated by destruction of the ankle joint with osteoarthritis. Recurrent lesions of the distal femur and the distal radius, previously treated by curettage and bone grafting healed under Denosumab and have remained stable for 2 and 3 years, respectively. One case of severe hypercalcemia was observed in a 7-year old child 6 months after discontinuation of Denosumab. Conclusion: Denosumab provides a treatment option for ABCs in anatomically critical locations. Adjuvant application might reduce the rate of local recurrence. In young patients, severe rebound hypercalcemia months after discontinuation of Denosumab may occur.

show abstract

Section: Discussionmentioning

confidence: 96%

“…To our best knowledge, 2 case series (with 9 patients each) have previously been published [18][19][20] with an additional 11 cases having been published as individual case reports [20][21][22][23][24][25][26][27][28][29].…”

Section: Introductionmentioning

confidence: 99%

Aneurysmal bone cyst: results of an off label treatment with Denosumab

Dürr¹,

Grahneis²,

Baur‐Melnyk

et al. 2019

BMC Musculoskelet Disord

View full text Add to dashboard Cite

show abstract

“…Denosumab provides meaningful clinical and radiological improvement in ABC. It may be a treatment option, especially for spinal lesions with potentially high surgical morbidity [18]. Lange et al [19] used denosumab in 2 pediatric patients aged 8 and 11 years with recurrent C5 ABCs, with good clinical and radiological short-term responses.…”

Section: Discussionmentioning

confidence: 99%

Cervical Spine Osteoblastoma with an Aneurysmal Bone Cyst in a 2-Year-Old Child: A Case Report

et al. 2019

View full text Add to dashboard Cite

Osteoblastomas and aneurysmal bone cysts are uncommon benign tumors of the spine. Their presentation can vary between diffuse pain, restriction of neck movements, torticollis, radiculopathy, and myelopathy. Complete excision is the best treatment to achieve a cure, but recurrence is not uncommon. A combination of the two conditions in the pediatric population is extremely rare. To the best of the authors’ knowledge, only 2 cases of such a combination in the cervical spine have been reported in the literature. We report the case of a 2-year-old child having a right C4 lateral mass osteoblastoma with an aneurysmal bone cyst. The child underwent complete surgical excision of the lesion with fusion.

show abstract

“…Advanced training after pediatric hematology/oncology fellowship is not unique to hemostasis and thrombosis. In fact, a survey of PHO Division Directors published in 2017 cited that 25% of graduates continued in a trainee level of subspecialty fellowship position, increasing from 16% in 2010 to 37% in 2015 . The ASPHO website lists a number of other post‐PHO fellowship programs for further specialization.…”

Section: Pho Subspecialty Training and The Workforcementioning

confidence: 99%

How we approach: Training pediatric coagulationists

Thornburg

Montgomery

Pipe

2019

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Unique expertise is required for the care of children, adolescents, and young adults with bleeding and clotting disorders. A number of Hemophilia Treatment Centers have developed pediatric hemostasis and thrombosis fellowship programs to facilitate subspecialty training and recruitment and retention in this field. This manuscript reviews an approach to training pediatric coagulationists including a description of current programs, sample curriculum, funding sources, and expected outcomes.

show abstract

The American Society of Pediatric Hematology/Oncology workforce assessment: Part 2—Implications for fellowship training

Cited by 14 publications

References 29 publications

Aneurysmal bone cyst: results of an off label treatment with Denosumab

Aneurysmal bone cyst: results of an off label treatment with Denosumab

Cervical Spine Osteoblastoma with an Aneurysmal Bone Cyst in a 2-Year-Old Child: A Case Report

How we approach: Training pediatric coagulationists

Contact Info

Product

Resources

About